Antiandrogens might help prevent or treat COVID-19 by blocking the virus's entry into cells.
April 2022 in “Brazilian Medical Students” People with androgenetic alopecia may have a higher risk of severe COVID-19.
5 citations,
December 2021 in “Scientific Reports” Age affects how certain proteins involved in COVID-19 infection are expressed in mice, but sex hormones and heart injury do not.
4 citations,
April 2021 in “Experimental and Molecular Medicine” The conclusion is that certain genetic factors and blood types may affect COVID-19 severity, but changes in ACE2 and TMPRSS2 genes are not clearly linked to it.
82 citations,
June 2020 in “Inflammation Research” Skin problems in COVID-19 patients are rare and may be due to the body's complex immune response or blood clotting issues.
42 citations,
June 2020 in “Seminars in Oncology” Sex hormones may affect COVID-19 severity, with men often faring worse, and targeting related pathways could offer treatment options.
38 citations,
December 2009 in “Therapeutic Advances in Medical Oncology” The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
36 citations,
July 2020 in “Frontiers in Medicine” Spironolactone might help protect against severe lung problems in COVID-19 patients.
15 citations,
December 2020 in “Pharmacology Research & Perspectives” Blocking enzymes that help the virus enter cells could be a promising way to treat COVID-19.
176 citations,
May 2020 in “Dermatologic Therapy” COVID-19 can cause different skin symptoms that may help with early diagnosis and show how severe the disease is.
80 citations,
June 2020 in “Dermatopathology” COVID-19 can cause various skin lesions, which may result from the virus and immune response, and are not directly linked to illness severity.
58 citations,
December 2020 in “Mayo Clinic Proceedings” The conclusion is that individual differences in COVID-19 severity are influenced by factors like age, sex, race, and genetics, which are important for personalized medicine.
34 citations,
September 2020 in “BMC Endocrine Disorders” Existing drug dexamethasone may lower death risk in severe COVID-19 cases; more research needed for other drugs.
21 citations,
January 2021 in “Therapeutic Advances in Endocrinology and Metabolism” Testosterone may have a dual role in COVID-19, potentially worsening outcomes in men, and testosterone therapy could help some patients, but more research is needed.
1 citations,
September 2020 in “Journal of the Endocrine Society” Men have worse COVID-19 outcomes than women due to genetic and hormonal differences.
January 2021 in “International Journal of Dermatology” Possible link between COVID-19 and hair loss; more research needed.
56 citations,
February 2006 in “American journal of physiology. Cell physiology” Steroid sex hormones activate matriptase in prostate cancer cells but not in breast cancer cells.
January 2023 in “Journal of men's health” Higher dihydrotestosterone may be linked to more inflammation in COVID-19 patients with low testosterone.
21 citations,
January 2021 in “Journal of infection and chemotherapy” Men, diabetes, and high inflammation levels lead to higher COVID-19 antibodies.
7 citations,
January 2021 in “The journal of gene medicine” Certain genetic differences may affect how likely someone is to get COVID-19 and how severe it might be.
February 2022 in “International journal of KIU” Certain genes and nutrients like vitamin D, zinc, and omega fatty acids affect COVID-19 severity and infection risk.
224 citations,
February 2013 in “The Journal of clinical investigation/The journal of clinical investigation” ERG increases SOX9, promoting prostate cancer growth and invasion.
15 citations,
April 2022 in “Immunology” Men and women get COVID-19 at similar rates, but men tend to get sicker and have a higher risk of dying, while women usually have stronger immune responses and vaccine reactions.
July 2023 in “International Journal of Molecular Sciences” Trapa bispinosa Roxb. extract may help reduce prostate size and cell growth in BPH.
1 citations,
January 2022 in “European Journal of Pharmacology” Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.
47 citations,
April 2020 in “Dermatologic Therapy” Androgenetic alopecia linked to COVID-19 severity; drugs reducing androgen receptor activation may help.
15 citations,
August 2021 in “Reviews in endocrine and metabolic disorders” COVID-19 and hypopituitarism (reduced pituitary gland function) are linked, with the latter's related health issues potentially worsening COVID-19 outcomes, and COVID-19 possibly increasing risk for pituitary complications.
5 citations,
May 2020 in “Dermatologic Therapy” 5-alpha reductase inhibitors might worsen lung recovery in COVID-19 patients, suggesting a pause in their use.
4 citations,
May 2021 in “Journal of The European Academy of Dermatology and Venereology” Hair loss doesn't affect COVID-19 severity.
1 citations,
March 2024 in “Signal transduction and targeted therapy” NF-κB signaling is crucial in many diseases and can be targeted for new treatments.